Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [23370]

ENEA 2010: A randomised, blinded, multicentre, Phase III study to assess the efficacy and safety of pasireotide LAR versus octreotide LAR in patients with active acromegaly

ENEA 2010: A randomised, blinded, multicentre, Phase III study to assess the efficacy and safety of pasireotide...

ENEA 2010: Pasireotide LAR versus octreotide LAR or lanreotide Autogel in patients with inadequately controlled acromegaly: A Phase III, multicentre, randomised, parallel-group study

ENEA 2010: Pasireotide LAR versus octreotide LAR or lanreotide Autogel in patients with inadequately controlled...

Targeted therapy decreases progression rate in thyroid cancer

Targeted therapy decreases progression rate in thyroid cancer

Selenium associated with a lower risk of bladder cancer

Selenium associated with a lower risk of bladder cancer

ENEA 2010: Challenges in determining diagnosis and remission in Cushing's disease

ENEA 2010: Challenges in determining diagnosis and remission in Cushing's disease

ENEA 2010: Cushing's disease: the high clinical burden resulting from chronic exposure to elevated cortisol

ENEA 2010: Cushing's disease: the high clinical burden resulting from chronic exposure to elevated cortisol

ENEA 2010: Potential new options for the treatment of Cushing's disease: the dawn of a new era?

ENEA 2010: Potential new options for the treatment of Cushing's disease: the dawn of a new era?

ENEA 2010: Management of acromegaly in 2020

ENEA 2010: Management of acromegaly in 2020

ENEA 2010: Otsuka Meet the Expert Session - Guidance for the use of novel therapies in the treatment of hyponatraemia

ENEA 2010: Otsuka Meet the Expert Session - Guidance for the use of novel therapies in the treatment of...

Breast cancer incidence in Canada declines as hormone therapy drops

Breast cancer incidence in Canada declines as hormone therapy drops

More from ecancer